Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors
ObjectiveThis article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1–4 mutations.MethodsSearch for relevant articles in databases such as PubMed, Embase, The Cochrane Library, Web of Science, and CNKI, covering the perio...
Saved in:
| Main Authors: | Jiyu Huang, Zihan Wang, Fei Zhao, Adilai Aisa, Shengkai Tian, Siyuan Chen, Lianyi Peng, Xiaolu Yang, Jianxin He, Yue Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1571434/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice
by: Hyun-ju Lee, et al.
Published: (2025-06-01) -
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
by: Maxim Noeraparast, et al.
Published: (2024-10-01) -
Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4
by: Qing Luo, et al.
Published: (2025-07-01) -
Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer
by: Huayuan Zhao, et al.
Published: (2025-05-01) -
Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer
by: Maximilian Haas, et al.
Published: (2025-07-01)